Nathalie Moll – Director General, European Federation of the Pharmaceutical Industries and Associations (EFPIA)

Keywords:

e-version image

Click HERE to download the PDF version

 

Politics and economics at European and world-wide level are like a great puzzle composed of many pieces. Some of these have changed radically (i.e in the USA) and others are changing their characteristics (in Europe, the national drift is increasingly strong, see Brexit – but not only). Politics and economics at European and world-wide level are like a great puzzle composed of many pieces. Some of these have changed radically (i.e in the USA) and others are changing their characteristics (in Europe, the national drift is increasingly strong, see Brexit – but not only). How does this wave of change relate to the business of European pharmaceutical companies and access to medicines by patients?
Research and development of new medicines for patients is a very long process, which normally takes 10-15 years. It is also an inherently risky process, where many promising research projects fail at some stage of this long development effort and the success rate is approxiamtely 10,000 candidate products t ...